Sumitomo Chemical invests in nucleic acid drug company Bonac

The investment is 4 billion Yen and expands Sumitomo’s share in the company to 19,55 %. Bonac is a specialist for modified RNA synthesis (Bonac nucleic acids) which exhibit good stability and may lead to novel mucleic acid drugs.

Source: Bonac news release, September 26, 2017

Request a quote for deeper information from

© 2018 Window to Japan - Bio 4 Business - Imprint